MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid tumour that affects around 2,000 people in the US each year. The green ...

MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a preventive antibody-based therapy for influenza. The agreement – first ...